Capricor Therapeutics, Inc.CAPRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -7.92% | -100.00% | -100.00% | -100.00% | -100.00% |
| Gross Profit Growth | -259.43% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +31.52% | +45.55% | +43.55% | +38.16% | +38.70% |
| Weighted Average Shares Diluted Growth | +31.52% | +45.55% | +43.55% | +38.16% | +38.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -0.03% | -83.78% | -83.92% | -85.56% | -99.43% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +190.26% | +210.99% | +248.95% | +36.03% | +108.79% |
| Book Value per Share Growth | +389.34% | +375.72% | +535.78% | -11.08% | +51.56% |
| Debt Growth | -35.10% | -38.17% | -43.16% | +782.17% | +1343.36% |
| R&D Expense Growth | +46.43% | +70.40% | +76.31% | +72.42% | +58.93% |
| SG&A Expenses Growth | +24.62% | +49.01% | +85.48% | +71.06% | +40.99% |